DK2575785T3 - Orale doseringsformer af bendamustin og terapeutisk anvendelse deraf - Google Patents

Orale doseringsformer af bendamustin og terapeutisk anvendelse deraf Download PDF

Info

Publication number: DK2575785T3
Authority: DK; Denmark
Prior art keywords: bendamustine; dosage forms; oral dosage; therapeutic use; therapeutic
Prior art date: 2010-06-02

Application number

DK11727917.4T

Other languages

English (en)

Inventor

Ulrich Patzak

Taoufik Ouatas

Original Assignee

Pharma& Schweiz Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-06-02

Filing date

2011-06-01

Publication date

2023-01-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44261747&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2575785(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-06-01 Application filed by Pharma& Schweiz Gmbh filed Critical Pharma& Schweiz Gmbh

2023-01-30 Application granted granted Critical

2023-01-30 Publication of DK2575785T3 publication Critical patent/DK2575785T3/da

Links

YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 title 1
229960002707 bendamustine Drugs 0.000 title 1
239000006186 oral dosage form Substances 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Oil, Petroleum & Natural Gas (AREA)
Oncology (AREA)
Inorganic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Mycology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Microbiology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK11727917.4T 2010-06-02 2011-06-01 Orale doseringsformer af bendamustin og terapeutisk anvendelse deraf DK2575785T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP10005762		2010-06-02
EP11075046		2011-03-14
PCT/EP2011/002763 WO2011151086A1 (en)	2010-06-02	2011-06-01	Oral dosage forms of bendamustine and therapeutic use thereof

Publications (1)

Publication Number	Publication Date
DK2575785T3 true DK2575785T3 (da)	2023-01-30

Family

ID=44261747

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK11727917.4T DK2575785T3 (da)	2010-06-02	2011-06-01	Orale doseringsformer af bendamustin og terapeutisk anvendelse deraf

Country Status (26)

Country	Link
US (2)	US20130209558A1 (da)
EP (1)	EP2575785B1 (da)
JP (2)	JP2013527206A (da)
KR (1)	KR101830147B1 (da)
CN (1)	CN103037852B (da)
AR (1)	AR081575A1 (da)
AU (1)	AU2011260614B2 (da)
BR (1)	BR112012030658B1 (da)
CA (1)	CA2800277A1 (da)
CL (1)	CL2012003340A1 (da)
CO (1)	CO6640268A2 (da)
DK (1)	DK2575785T3 (da)
EA (1)	EA027786B1 (da)
ES (1)	ES2935792T3 (da)
FI (1)	FI2575785T3 (da)
IL (2)	IL223309B (da)
JO (1)	JO3659B1 (da)
MX (1)	MX2012013873A (da)
MY (1)	MY173881A (da)
NZ (1)	NZ603874A (da)
PH (1)	PH12012502282B1 (da)
PL (1)	PL2575785T3 (da)
SG (1)	SG185794A1 (da)
TW (1)	TWI556819B (da)
WO (1)	WO2011151086A1 (da)
ZA (1)	ZA201208822B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2758052B9 (en) *	2011-09-18	2019-03-27	Euro-Celtique S.A.	Pharmaceutical composition comprising an HDAC inhibitor and a cyclopolysaccharide
TWI573792B (zh)	2012-02-01	2017-03-11	歐陸斯迪公司	新穎治療劑
EP2641592A1 (en)	2012-03-23	2013-09-25	Salmon Pharma GmbH	Pharmaceutical formulation comprising bendamustine
DK2656843T3 (da)	2012-04-26	2015-04-20	Helmut Schickaneder	Estere af bendamustin og relaterede forbindelser, og medicinsk anvendelse deraf
WO2014106962A1 (ko) *	2013-01-07	2014-07-10	삼아제약 주식회사	향상된 용해도를 갖는 신규한 속용성 과립제형
CN109953954A (zh) *	2013-08-27	2019-07-02	V·沃道里斯	苯达莫司汀医药组合物
GB201409471D0 (en)	2014-05-28	2014-07-09	Euro Celtique Sa	Pharmaceutical composition
GB201409485D0 (en)	2014-05-28	2014-07-09	Euro Celtique Sa	Pharmaceutical composition
GB201409488D0 (en)	2014-05-28	2014-07-09	Euro Celtique Sa	Pharmaceutical composition
CN105726472B (zh) *	2016-03-25	2019-12-13	南京康玻斯医药科技有限公司	苯达莫司汀药剂组合物及应用
US11266631B2 (en)	2016-10-11	2022-03-08	Purdue Pharmaceutical Products L.P.	Hodgkin lymphoma therapy
GB201709403D0 (en)	2017-06-13	2017-07-26	Euro Celtique Sa	Compounds for treating sarcoma
GB201709402D0 (en)	2017-06-13	2017-07-26	Euro Celtique Sa	Compounds for treating t-pll
GB201709406D0 (en)	2017-06-13	2017-07-26	Euro-Cletique S A	Compounds for treating TNBC
GB201709405D0 (en)	2017-06-13	2017-07-26	Euro Celtique Sa	Compounds for treating ovarian cancer
WO2020128913A1 (en)	2018-12-18	2020-06-25	Mundipharma International Corporation Limited	Compounds for treating multiple myeloma
CN112848583B (zh) *	2020-12-31	2022-08-05	雅达环保科技(玉田)有限公司	一种阻燃保温板及其制备方法
WO2023113650A1 (ru) *	2021-12-15	2023-06-22	Владимир Евгеньевич НЕБОЛЬСИН	Фармацевтическая композиция 1-[2-(1-метилимидазол-4-ил)-этил]пергидроазин-2,6-дион для терапии заболеваний верхних дыхательных путей

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE159289C (da) *	1903-10-08	1905-03-16
US20040072889A1 (en) *	1997-04-21	2004-04-15	Pharmacia Corporation	Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
DE19826517B4 (de) *	1998-06-15	2006-03-23	Baxter Healthcare S.A.	Verfahren zur Herstellung von Filmtabletten mit Cyclophosphamid als Wirkstoff und daraus hergestellte Cyclophosphamid-Filmtablette
US7374779B2 (en)	1999-02-26	2008-05-20	Lipocine, Inc.	Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6395300B1 (en) *	1999-05-27	2002-05-28	Acusphere, Inc.	Porous drug matrices and methods of manufacture thereof
US20030105141A1 (en)	2001-04-17	2003-06-05	Ping Gao	Finely self-emulsifiable pharmaceutical composition
DE10304403A1 (de) *	2003-01-28	2004-08-05	Röhm GmbH & Co. KG	Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
US7423004B2 (en)	2003-01-31	2008-09-09	Smithkline Beecham Corporation	Solid dispersion compositions
JP2006514119A (ja) *	2003-02-12	2006-04-27	アールアンドピーコリアカンパニーリミテッド	溶解率が向上した難溶性薬剤の溶媒系
HRP20050934B1 (hr) *	2003-04-04	2014-09-26	Genentech, Inc.	Formulacije s visokom koncentracijom antitijela i proteina
EP1814544A4 (en) *	2004-11-05	2009-12-02	Cephalon Inc	CANCER TREATMENTS
US8436190B2 (en)	2005-01-14	2013-05-07	Cephalon, Inc.	Bendamustine pharmaceutical compositions
EP2144601A4 (en) *	2007-04-05	2012-10-10	Univ Kansas	RAPID DISSOLVING PHARMACEUTICAL COMPOSITIONS COMPRISING PULLULANE
AU2008274941A1 (en)	2007-07-12	2009-01-15	Tragara Pharmaceuticals, Inc.	Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
US20100209927A1 (en) *	2007-11-06	2010-08-19	Menon Vinod P	Processing device tablet
AR072777A1 (es)	2008-03-26	2010-09-22	Cephalon Inc	Formas solidas de clorhidrato de bendamustina
HRP20180709T1 (hr) *	2008-06-06	2018-06-15	Boehringer Ingelheim International Gmbh	Farmaceutski dozni oblik kapsule koji obuhvaća suspenzijsku formulaciju derivata indolinona
US8349353B2 (en)	2008-06-27	2013-01-08	Otonomy, Inc.	Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
UA107186C2 (xx) *	2008-12-03	2014-12-10		Тверді форми дозування бендамустину
HRP20140204T1 (hr) *	2008-12-03	2014-04-11	Astellas Deutschland Gmbh	Oralni oblici doziranja bendamustina
US20100273730A1 (en) *	2009-04-27	2010-10-28	Innopharmax, Inc.	Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
CN102413816A (zh) *	2009-04-28	2012-04-11	赛福伦公司	苯达莫司汀的口服制剂
US20100297194A1 (en)	2009-04-30	2010-11-25	Nathaniel Catron	Formulation for oral administration of apoptosis promoter

2011
- 2011-05-31 JO JOP/2011/0179A patent/JO3659B1/ar active
- 2011-06-01 JP JP2013512794A patent/JP2013527206A/ja active Pending
- 2011-06-01 PH PH1/2012/502282A patent/PH12012502282B1/en unknown
- 2011-06-01 BR BR112012030658-8A patent/BR112012030658B1/pt not_active IP Right Cessation
- 2011-06-01 NZ NZ603874A patent/NZ603874A/en not_active IP Right Cessation
- 2011-06-01 US US13/701,228 patent/US20130209558A1/en not_active Abandoned
- 2011-06-01 EA EA201291249A patent/EA027786B1/ru unknown
- 2011-06-01 FI FIEP11727917.4T patent/FI2575785T3/fi active
- 2011-06-01 DK DK11727917.4T patent/DK2575785T3/da active
- 2011-06-01 SG SG2012087797A patent/SG185794A1/en unknown
- 2011-06-01 EP EP11727917.4A patent/EP2575785B1/en active Active
- 2011-06-01 KR KR1020127033703A patent/KR101830147B1/ko not_active Expired - Fee Related
- 2011-06-01 CA CA2800277A patent/CA2800277A1/en not_active Abandoned
- 2011-06-01 AU AU2011260614A patent/AU2011260614B2/en not_active Ceased
- 2011-06-01 CN CN201180038034.4A patent/CN103037852B/zh not_active Expired - Fee Related
- 2011-06-01 ES ES11727917T patent/ES2935792T3/es active Active
- 2011-06-01 MY MYPI2012701043A patent/MY173881A/en unknown
- 2011-06-01 WO PCT/EP2011/002763 patent/WO2011151086A1/en not_active Ceased
- 2011-06-01 MX MX2012013873A patent/MX2012013873A/es unknown
- 2011-06-01 PL PL11727917.4T patent/PL2575785T3/pl unknown
- 2011-06-02 AR ARP110101916A patent/AR081575A1/es not_active Application Discontinuation
- 2011-06-02 TW TW100119386A patent/TWI556819B/zh not_active IP Right Cessation
2012
- 2012-11-22 ZA ZA2012/08822A patent/ZA201208822B/en unknown
- 2012-11-27 IL IL223309A patent/IL223309B/en active IP Right Grant
- 2012-11-29 CL CL2012003340A patent/CL2012003340A1/es unknown
- 2012-12-10 CO CO12223428A patent/CO6640268A2/es not_active Application Discontinuation
2015
- 2015-03-18 US US14/661,693 patent/US10485787B2/en active Active
2016
- 2016-06-03 JP JP2016112212A patent/JP6259490B2/ja active Active
2020
- 2020-02-06 IL IL272501A patent/IL272501A/en unknown

Also Published As

Publication number	Publication date
PL2575785T3 (pl)	2023-02-20
JP2016172763A (ja)	2016-09-29
CL2012003340A1 (es)	2014-03-28
SG185794A1 (en)	2013-01-30
JP6259490B2 (ja)	2018-01-10
US10485787B2 (en)	2019-11-26
EA027786B1 (ru)	2017-09-29
PH12012502282B1 (en)	2019-06-14
EP2575785B1 (en)	2022-10-26
EP2575785A1 (en)	2013-04-10
AU2011260614B2 (en)	2016-12-15
CA2800277A1 (en)	2011-12-08
MY173881A (en)	2020-02-26
FI2575785T3 (fi)	2023-01-31
JO3659B1 (ar)	2020-08-27
CO6640268A2 (es)	2013-03-22
ZA201208822B (en)	2014-08-27
CN103037852B (zh)	2016-06-15
AR081575A1 (es)	2012-10-03
TW201210591A (en)	2012-03-16
BR112012030658B1 (pt)	2022-08-02
KR101830147B1 (ko)	2018-02-20
IL272501A (en)	2020-03-31
PH12012502282A1 (en)	2013-02-11
IL223309A0 (en)	2013-02-03
TWI556819B (zh)	2016-11-11
MX2012013873A (es)	2013-07-03
IL223309B (en)	2020-05-31
EA201291249A1 (ru)	2014-07-30
JP2013527206A (ja)	2013-06-27
ES2935792T3 (es)	2023-03-10
US20130209558A1 (en)	2013-08-15
NZ603874A (en)	2014-08-29
WO2011151086A1 (en)	2011-12-08
AU2011260614A1 (en)	2013-01-10
US20150258070A1 (en)	2015-09-17
BR112012030658A2 (pt)	2016-08-16
KR20130116164A (ko)	2013-10-23
CN103037852A (zh)	2013-04-10

Publication	Publication Date	Title
DK2575785T3 (da)	2023-01-30	Orale doseringsformer af bendamustin og terapeutisk anvendelse deraf
DK3045043T3 (da)	2020-08-03	Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse
DK2528602T4 (da)	2020-04-27	Formuleringer af bendamustin
IL222132B (en)	2018-04-30	Use of cannabidivarin for the preparation of medicaments for treating epilepsy or epileptic seizures
DK2742857T3 (da)	2019-05-20	Integration af intra-oral afbildning og volumetrisk afbildning
EP2400987A4 (en)	2012-08-22	Benda MUSTIN-CYCLOPOLYSACCHARIDZUSAMMENSETZUNGEN
DK2531181T3 (da)	2019-07-15	Formuleringer af rasagilin med forlænget afgivelse og anvendelser deraf
DK2968155T3 (da)	2021-04-19	Orale tofacitinib-doseringsformer med langvarig frigivelse
DK2884979T3 (da)	2019-09-02	Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
EP2467093A4 (en)	2015-06-17	JOINT DEPLOYMENT DEVICE AND METHOD OF USE
PT2732818T (pt)	2017-08-07	Antagonista do receptor da angiotensina ii e da endotelina bifenilsulfonamida para tratamento da glomerulosclerose
FI20105569L (fi)	2011-11-25	Kehonsisäinen hoitolaite
HRP20170972T1 (hr)	2017-09-22	Kombinacijska terapija afukoziliranog cd20-protutijela s bendamustinom
EP2549986A4 (en)	2016-03-02	MACROPHONE LEAVE TO MULTIPLE OBJECTIVES
DK2367542T3 (da)	2014-03-10	Orale doseringsformer af bendamustin
PL2771037T3 (pl)	2017-06-30	Środki terapeutyczne i ich zastosowania
DK3603704T3 (da)	2023-07-24	Indgivelse af medikament
DK3095441T3 (da)	2021-01-11	Hurtigt opløsende doseringsform af en oral vaccine under anvendelse af stivelse
FI20135146L (fi)	2013-02-15	Farmaseuttiset koostumukset ja hoitomenetelmät
NL301214I2 (nl)	2023-04-19	Lasmiditan en farmaceutisch aanvaardbare zouten daarvan
PL2582366T3 (pl)	2016-04-29	Kombinacja farmaceutyczna do leczenia bólu
DK2827862T3 (da)	2024-02-12	Formuleringer af bendamustin
DK3199533T3 (da)	2019-05-20	Pyrazolforbindelse og farmaceutisk anvendelse deraf
DK2411009T3 (da)	2013-06-24	Terapeutiske anvendelser af quinazolindionderivater
DK2403354T3 (da)	2013-04-08	Formulering af astaxanthin-derivater og anvendelse heraf